Why India
India — The World's Emerging Clinical Trials Powerhouse
Key Statistics:
- 1.4 Billion+ — Diverse patient population across all demographics
- 40–60% Lower — Clinical trial operational costs vs. US/EU
- 3,500+ — GCP-compliant clinical trial sites nationwide
- 700+ — DCGI-approved trials annually
- #3 Globally — In pharmaceutical production capacity
India has rapidly transformed into one of the world's most strategic destinations for clinical research. A vast treatment-naïve patient population, competitive operational costs, a robust regulatory modernization trajectory under CDSCO and the New Drugs & Clinical Trials Rules (2019), and a deep bench of medically trained investigators make India the market of choice for sponsors seeking speed, scale, and scientific quality.
Zetalix is positioned at the intersection of India's clinical trial ecosystem and global standards — ensuring every study meets ICH-GCP benchmarks while leveraging India's unique advantages in recruitment velocity, therapeutic diversity, and cost efficiency.
Clinical Trial Workflow
Our Proven Clinical Trial Workflow — Product Evaluation to Market Launch
Every clinical program is unique. Zetalix builds a customized regulatory and operational roadmap for each sponsor — reducing timelines, mitigating risk, and ensuring compliance from Day 1 to market authorization.